Reilly T G, Grimley C E, Usselmann B, Cottrell J, Mann S G, Raskin S, Nwokolo C U
Department of Gastroenterology, Walsgrave Hospital, Coventry, UK.
Aliment Pharmacol Ther. 1998 May;12(5):469-74. doi: 10.1046/j.1365-2036.1998.00323.x.
Amongst the low-dose H2-receptor antagonists available for the self-medication of dyspepsia, both famotidine 10 mg and cimetidine 200 mg have been shown to raise intragastric pH, but there is a delay after ingestion before significant effects can be demonstrated. A new effervescent preparation of cimetidine 200 mg releases an acid buffer which has a more rapid effect on intragastric pH.
To investigate the relative abilities of low-dose famotidine and effervescent cimetidine to raise intragastric pH after a single postprandial evening dose.
Twenty-four healthy subjects (12 men, 12 women, median age 32 years) completed a three-period crossover trial of famotidine 10 mg, effervescent cimetidine 200 mg and placebo. After a standard meal was given at 18.30 h to subjects fasted for 5.5 h, drug or placebo was given at 19.30 h. Intragastric pH was recorded with combined glass electrodes from 18.00 to 07.30 h by digital recorders.
Over the 12 h post-dose period the mean area under the pH/time curve (AUC) after famotidine 10 mg was 3.73, after cimetidine 200 mg effervescent 2.79, and after placebo 2.07. Over the same period the median pH and percentage of time that recordings were above pH 3 were 3.45 and 52.5 after famotidine 10 mg, 2.40 and 33.8 after cimetidine 200 mg effervescent, and 1.68 and 15.9 after placebo. Both active treatments were significantly different from placebo by each measure (P < 0.001), and famotidine 10 mg was significantly more effective than cimetidine 200 mg effervescent by each measure over the 0-12 h period (P < 0.001). Comparisons of mean AUCs for each 15 min period after dosing showed that decrease in acidity was significantly greater after cimetidine 200 mg effervescent than after famotidine 10 mg for the first 60 min. In the later post-dose period only famotidine 10 mg raised pH for all time points to 12 h, whilst the effect of effervescent cimetidine 200 mg was detectable to = 8 h.
Inhibition of gastric acidity over the 12 h post-dose period was significantly greater and endured longer after famotidine 10 mg than after effervescent cimetidine 200 mg, but for the 60 min period immediately after dosing the effect on intragastric pH was significant following effervescent cimetidine 200 mg but not famotidine 10 mg. This suggests effervescent formulations of H2-receptor antagonists with an acid buffer have a more rapid effect on intragastric pH than film-coated tablets.
在可用于消化不良自我治疗的低剂量H2受体拮抗剂中,法莫替丁10毫克和西咪替丁200毫克均已显示可提高胃内pH值,但摄入后有延迟,才能显示出显著效果。一种新的200毫克西咪替丁泡腾制剂可释放一种酸缓冲剂,对胃内pH值有更快的作用。
研究单次餐后夜间剂量的低剂量法莫替丁和泡腾西咪替丁提高胃内pH值的相对能力。
24名健康受试者(12名男性,12名女性,中位年龄32岁)完成了一项为期三期的交叉试验,分别服用10毫克法莫替丁、200毫克泡腾西咪替丁和安慰剂。在18:30给禁食5.5小时的受试者提供标准餐后,于19:30给予药物或安慰剂。通过数字记录仪,使用组合玻璃电极从18:00至07:30记录胃内pH值。
在给药后的12小时内,10毫克法莫替丁后的pH/时间曲线下平均面积(AUC)为3.73,200毫克泡腾西咪替丁后的为2.79,安慰剂后的为2.07。在同一时期,10毫克法莫替丁后的pH中位数和记录高于pH 3的时间百分比分别为3.45和52.5,200毫克泡腾西咪替丁后的为2.40和33.8,安慰剂后的为1.68和15.9。两种活性治疗在各项指标上均与安慰剂有显著差异(P < 0.001),并且在0至12小时期间,10毫克法莫替丁在各项指标上均比200毫克泡腾西咪替丁显著更有效(P < 0.001)。给药后每个15分钟时间段的平均AUC比较显示,在前60分钟内,200毫克泡腾西咪替丁后的酸度降低显著大于10毫克法莫替丁后的。在给药后的后期,只有10毫克法莫替丁在所有时间点将pH值提高至12小时,而200毫克泡腾西咪替丁的作用在8小时内可检测到。
给药后12小时内,10毫克法莫替丁对胃酸的抑制作用比200毫克泡腾西咪替丁显著更强且持续时间更长,但在给药后立即的60分钟内,200毫克泡腾西咪替丁对胃内pH值有显著作用,而10毫克法莫替丁则没有。这表明含有酸缓冲剂的H2受体拮抗剂泡腾制剂对胃内pH值的作用比薄膜包衣片更快。